바이오소재 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 지역별, 부문별 예측(2026-2033년)

Biomaterials Market Size, Share & Trends Analysis Report By Product (Natural, Metallic, Polymer), By Application (Cardiovascular, Orthopedics, Plastic Surgery), By Region, And Segment Forecasts, 2026 - 2033

US $ 5,950 ￦ 8,615,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,062,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,958,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

바이오소재 시장 요약

세계의 바이오소재 시장 규모는 2025년에 2,369억 9,000만 달러로 추정되며, 2033년까지 8,365억 4,000만 달러에 달할 것으로 예측됩니다.

2026년부터 2033년까지 CAGR 17.25%로 성장할 것으로 예상됩니다. 근골격계 및 만성 골격계 질환의 발생률 증가는 생체재료 기반 임플란트 수요를 자극하여 시장 확대를 촉진할 것으로 예상됩니다.

첨단 수술 기법의 보급

최소침습적이고 기술적으로 진보된 외과 수술로의 전환은 바이오소재에 대한 수요를 가속화하는 주요 촉진제입니다. 의료진은 입원기간 단축, 수술 후 합병증 감소, 환자 회복기간 개선이 가능하기 때문에 최소침습적 기술의 도입을 확대하고 있습니다. 이러한 수술에는 경량, 고강도, 생체적합성, 생체흡수성을 갖춘 고도로 전문화된 생체 재료가 필요합니다. 그 결과, 정형외과, 심혈관, 일반외과 분야에서 첨단 고분자, 복합재료, 생리활성물질에 대한 수요가 꾸준히 증가하고 있습니다.

로봇 보조 수술, 영상 유도 치료, 카테터 기반 시술의 보급 확대는 우수한 기계적 및 생물학적 성능을 갖춘 정밀 설계 바이오소재의 필요성을 더욱 강화시키고 있습니다. 이러한 시술에 사용되는 생체재료는 안전성과 장기적인 기능성을 보장하기 위해 향상된 유연성, 제어된 분해성, 강력한 조직과의 상호작용을 제공해야 합니다. 이를 통해 생체흡수성 스텐트, 최소침습성 정형외과 임플란트, 연조직 스캐폴드 분야의 혁신을 촉진하고, 외과 의사가 더 높은 시술 정확도와 환자 치료 결과를 개선할 수 있도록 돕습니다.

또한, 환자의 인식 개선, 의료 접근성 확대, 만성질환의 증가 등의 요인도 첨단 수술 솔루션의 보급에 기여하고 있습니다. 최소침습수술은 재활 비용과 재수술률을 낮춰 장기적으로 비용 효율성이 높기 때문에 선호되고 있습니다. 이러한 외과 의료 행위의 구조적 변화는 고성능 바이오소재에 대한 지속적인 수요를 강화하여 세계 바이오소재 산업의 중요한 성장 동력이 되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 바이오소재 시장 : 주요 요약

• 시장 개요
• 부문 개요
• 경쟁 구도 개요

제3장 바이오소재 시장 변수, 동향, 범위

• 시장 세분화와 범위
• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
• 바이오소재 시장 분석 툴
  • 업계 분석 : Porter's Five Forces
  • PESTLE 분석

제4장 바이오소재 시장 : 제품별 추정·동향 분석

• 세계의 바이오소재 시장 : 제품별 변동 분석
• 세계의 바이오소재 시장 규모와 동향 분석 : 제품별, 2021-2033년
  • 금속
  • 천연
  • 세라믹
  • 폴리머

제5장 바이오소재 시장 : 용도별 추정·동향 분석

• 세계의 바이오소재 시장 : 용도별 변동 분석
• 세계의 바이오소재 시장 규모와 동향 분석 : 용도별, 2021-2033년
  • 심혈관
  • 안과
  • 치과
  • 정형외과
  • 상처 치유
  • 조직공학
  • 성형외과
  • 신경
  • 기타

제6장 지역별 비즈니스 분석

• 지역별 시장 점유율 분석, 2025년·2033년
• 시장 규모와 예측 동향 분석, 2021-2033년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 스페인
  • 프랑스
  • 이탈리아
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 태국
  • 호주
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진입 기업별 최근 동향과 영향 분석
• 세계 시장 시장 상황 분석
• 기업/경쟁 분류
  • Medtronic
  • Evonik Industries AG
  • Carpenter Technology Corporation
  • Berkeley Advanced Biomaterials
  • Invibio Ltd
  • Zimmer Biomet Holdings, Inc.
  • BASF SE
  • Covalon Technologies Ltd
  • Stryker
  • Johnson & Johnson
  • Dentsply Sirona
  • CoorsTek Inc
  • Corbion
  • Regenity Biosciences

KSM

영문 목차

영문목차

Biomaterials Market Summary

The global biomaterials market size was estimated at USD 236.99 billion in 2025 and is projected to reach USD 836.54 billion by 2033, growing at a CAGR of 17.25% from 2026 to 2033. The growing incidence of musculoskeletal and chronic skeletal medical conditions is expected to stimulate the demand for implants based on biomaterials, thereby enhancing market expansion.

Rise of Advanced Surgical Procedures

The global shift toward minimally invasive and technologically advanced surgical procedures is a major driver accelerating demand for biomaterials. Healthcare providers are increasingly adopting minimally invasive techniques due to their ability to reduce hospital stays, lower post-operative complications, and improve patient recovery timelines. These procedures require highly specialized biomaterials that are lightweight, high-strength, biocompatible, and often bioresorbable. As a result, demand for advanced polymers, composites, and bioactive materials is rising steadily across orthopedic, cardiovascular, and general surgical applications.

The growing use of robotic-assisted surgery, image-guided interventions, and catheter-based procedures is further strengthening the need for precision-engineered biomaterials with superior mechanical and biological performance. Biomaterials used in these procedures must offer enhanced flexibility, controlled degradation, and strong tissue interaction to ensure safety and long-term functionality. This is driving innovations in bioresorbable stents, minimally invasive orthopedic implants, and soft tissue scaffolds, enabling surgeons to achieve better procedural accuracy and improved patient outcomes.

In addition, increasing patient awareness, rising healthcare accessibility, and the growing burden of chronic diseases are contributing to the widespread adoption of advanced surgical solutions. Minimally invasive procedures are being favored for their cost-effectiveness over the long term, as they reduce rehabilitation expenses and revision surgery rates. This structural shift in surgical practice is reinforcing sustained demand for high-performance biomaterials, making it a critical growth engine for the global biomaterials industry.

Global Biomaterials Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global biomaterials market report on the basis of product, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Metallic
• Natural
• Ceramics
• Polymers
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular
  • Sensors
  • Stents
  • Guidewires
  • Implantable Cardiac Defibrillators
  • Pacemakers
  • Vascular Grafts
  • Others
• Ophthalmology
  • Synthetic Corneas
  • Intraocular Lens
  • Contact Lens
  • Ocular Tissue Replacement
  • Others
• Dental
  • Tissue Regeneration Materials
  • Dental Implants
  • Bone Grafts & Substitutes
  • Dental Membranes
  • Others
• Orthopedics
  • Joint Replacement biomaterials
  • Orthobiologics
  • Bioresorbable Tissue Fixation Products
  • Viscosupplementation
  • Spine Biomaterials
  • Others
• Wound Healing
  • Fracture Healing Device
  • Adhesion Barrier
  • Skin Substitutes
  • Internal Tissue Sealant
  • Surgical Hemostats
  • Others
• Tissue Engineering
• Plastic Surgery
  • Facial Wrinkle Treatment
  • Soft Tissue Fillers
  • Craniofacial Surgery
  • Bioengineered Skins
  • Peripheral Nerve Repair
  • Acellular Dermal Matrices
  • Others
• Neurology
  • Neural Stem Cell Encapsulation
  • Shunting Systems
  • Hydrogel Scaffold For CNS Repair
  • Cortical Neural Prosthetics
  • Others
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation And Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List Of Primary Sources
• 1.11. List Of Abbreviations

Chapter 2. Biomaterials Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshots
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biomaterials Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising Demand As A Consequence Of Accidental Injuries & Chronic Conditions
    • 3.3.1.2. Advances In Biomaterials Technologies
    • 3.3.1.3. Expansion In The Usage Scope Of Biomaterials
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. High Expense Associated With The Development Of Biomaterials
    • 3.3.2.2. Problems Related To Biocompatibility Of Biomaterials
• 3.4. Biomaterials Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTLE Analysis

Chapter 4. Biomaterials: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Biomaterials Market Product Movement Analysis
• 4.3. Global Biomaterials Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.3.1. Metallic
    • 4.3.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 4.3.2. Natural
    • 4.3.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 4.3.3. Ceramics
    • 4.3.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 4.3.4. Polymers
    • 4.3.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)

Chapter 5. Biomaterials: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Biomaterials Market Application Movement Analysis
• 5.3. Global Biomaterials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.3.1. Cardiovascular
    • 5.3.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.1. Sensors
        • 5.3.1.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.2. Stents
        • 5.3.1.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.3. Guidewires
        • 5.3.1.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.4. Implantable Cardiac Defibrillators
        • 5.3.1.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.5. Pacemakers
        • 5.3.1.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.6. Vascular Grafts
        • 5.3.1.1.6.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.1.1.7. Others
        • 5.3.1.1.7.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.2. Ophthalmology
    • 5.3.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.2.1.1. Synthetic Corneas
        • 5.3.2.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.2.1.2. Intraocular Lens
        • 5.3.2.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.2.1.3. Contact Lens
        • 5.3.2.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.2.1.4. Ocular Tissue Replacement
        • 5.3.2.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.2.1.5. Others
        • 5.3.2.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.3. Dental
    • 5.3.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.3.1.1. Tissue Regeneration Materials
        • 5.3.3.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.3.1.2. Dental Implants
        • 5.3.3.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.3.1.3. Bone Grafts & Substitutes
        • 5.3.3.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.3.1.4. Dental Membranes
        • 5.3.3.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.3.1.5. Others
        • 5.3.3.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.4. Orthopedic
    • 5.3.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.4.1.1. Joint Replacement biomaterials
        • 5.3.4.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.4.1.2. Orthobiologics
        • 5.3.4.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.4.1.3. Bioresorbable Tissue Fixation Products
        • 5.3.4.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.4.1.4. Visco supplementation
        • 5.3.4.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.4.1.5. Spine Biomaterial
        • 5.3.4.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.4.1.6. Others
        • 5.3.4.1.6.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.5. Wound Healing
    • 5.3.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.5.1.1. Fracture Healing Device
        • 5.3.5.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.5.1.2. Adhesion Barrier
        • 5.3.5.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.5.1.3. Skin Substitutes
        • 5.3.5.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.5.1.4. Internal Tissue Sealant
        • 5.3.5.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.5.1.5. Surgical Hemostats
        • 5.3.5.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.5.1.6. Others
        • 5.3.5.1.6.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.6. Tissue Engineering
    • 5.3.6.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.7. Plastic Surgery
    • 5.3.7.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.1. Facial Wrinkle Treatment
        • 5.3.7.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.2. Soft Tissue Fillers
        • 5.3.7.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.3. Craniofacial Surgery
        • 5.3.7.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.4. Bioengineered Skins
        • 5.3.7.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.5. Peripheral Nerve Repair
        • 5.3.7.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.6. Acellular Dermal Matrices
        • 5.3.7.1.6.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.7.1.7. Others
        • 5.3.7.1.7.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.8. Neurology
    • 5.3.8.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.8.1.1. Neural Stem Cell Encapsulation
        • 5.3.8.1.1.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.8.1.2. Shunting Systems
        • 5.3.8.1.2.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.8.1.3. Hydrogel Scaffold For CNS Repair
        • 5.3.8.1.3.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.8.1.4. Cortical Neural Prosthetics
        • 5.3.8.1.4.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
      • 5.3.8.1.5. Others
        • 5.3.8.1.5.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 5.3.9. Others
    • 5.3.9.1. Market Estimates And Forecasts 2021 To 2033 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Marker Size, & Forecasts Trend Analysis, 2021 To 2033:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key Country Dynamics
    • 6.3.1.2. Competitive Scenario
    • 6.3.1.3. Regulatory Framework
    • 6.3.1.4. U.S. Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Canada Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Mexico Market Estimates And Forecasts 2021 To 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Competitive Scenario
    • 6.4.1.3. Regulatory Framework
    • 6.4.1.4. UK Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Germany Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.3. Spain
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Spain Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. France Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Italy Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.6. Denmark
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Denmark Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Sweden Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Norway Market Estimates And Forecasts 2021 To 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Competitive Scenario
    • 6.5.1.3. Regulatory Framework
    • 6.5.1.4. Japan Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. China Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. India Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.5.4. South Korea
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. South Korea Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Thailand Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.5.6. Australia
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Australia Market Estimates And Forecasts 2021 To 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Competitive Scenario
    • 6.6.1.3. Regulatory Framework
    • 6.6.1.4. Brazil Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Argentina Market Estimates And Forecasts 2021 To 2033 (USD Million)
• 6.7. Middle East and Africa
  • 6.7.1. South Africa
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Competitive Scenario
    • 6.7.1.3. Regulatory Framework
    • 6.7.1.4. South Africa Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Saudi Arabia Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. UAE Market Estimates And Forecasts 2021 To 2033 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Kuwait Market Estimates And Forecasts 2021 To 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Global Market Position Analysis
• 7.3. Company /Competition Categorization
  • 7.3.1. Medtronic
    • 7.3.1.1. Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Product Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Evonik Industries AG
    • 7.3.2.1. Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Product Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Carpenter Technology Corporation
    • 7.3.3.1. Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Product Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Berkeley Advanced Biomaterials
    • 7.3.4.1. Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Product Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Invibio Ltd
    • 7.3.5.1. Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Product Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. Zimmer Biomet Holdings, Inc.
    • 7.3.6.1. Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Product Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. BASF SE
    • 7.3.7.1. Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Product Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Covalon Technologies Ltd
    • 7.3.8.1. Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Product Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Stryker
    • 7.3.9.1. Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Product Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Johnson & Johnson
    • 7.3.10.1. Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Product Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Dentsply Sirona
    • 7.3.11.1. Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Product Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. CoorsTek Inc
    • 7.3.12.1. Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Product Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Corbion
    • 7.3.13.1. Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Product Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Regenity Biosciences
    • 7.3.14.1. Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Product Benchmarking
    • 7.3.14.4. Strategic Initiatives

관련자료